Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 322

Sort by

Sort Order Select

Journal Articles

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang, Jan Philipp Bewersdorf, Maximilian Stahl, Amy E. DeZern, Uwe Platzbecker, Mikkael A. Sekeres, Andrew H. Wei, Rena J. Buckstein, Gail J. Roboz, Michael R. Savona, Sanam Loghavi, Robert P. Hasserjian, Pierre Fenaux, David A. Sallman, Christopher S. Hourigan, Matteo Giovanni Della Porta, Stephen Nimer, Richard F. Little, Valeria Santini, Fabio Efficace, Justin Taylor, Guillermo Garcia-Manero, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami S. Komrokji, Elizabeth A. Griffiths, Peter L. Greenberg, Mina L. Xu, Zhuoer Xie, Rafael Bejar, Guillermo F. Sanz, Mrinal M. Patnaik, Maria Figueroa, Hetty E. Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval G. Daver, Jane E. Churpek, Ravindra Majeti, John M. Bennett, Alan F. List, Andrew M. Brunner, Amer M. Zeidan

Blood (2025) 145 (13): 1369–1381.

https://doi.org/10.1182/blood.2023023717

Published: 2025

Includes: Supplemental data

Journal Articles

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Luca Lanino, Somedeb Ball, Jan Philipp Bewersdorf, Monia Marchetti, Giulia Maggioni, Erica Travaglino, Najla H Al Ali, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Maria Diez-Campelo, Avani M Singh, Akriti Gupta Jain, Luis E. Aguirre, Sara M. Tinsley-Vance, Zaker I. Schwabkey, Onyee Chan, Zhuoer Xie, Andrew M. Brunner, Andrew T. Kuykendall, John M. Bennett, Rena Buckstein, Rafael Bejar, Hetty E. Carraway, Amy E. DeZern, Elizabeth A. Griffiths, Stephanie Halene, Robert Hasserjian, Jeffrey Lancet, Alan F. List, Sanam Loghavi, Olatoyosi Odenike, Eric Padron, Mrinal M. Patnaik, Gail J. Roboz, Maximilian Stahl, Mikkael A. Sekeres, David Peter Steensma, Michael R. Savona, Justin Taylor, Mina Xu, Kendra Sweet, David A Sallman, Stephen D. Nimer, Christopher S. Hourigan, Andrew H. Wei, Elisabetta Sauta, Saverio D'Amico, Gianluca Asti, Gastone Castellani, Uma M. Borate, Guillermo Sanz, Fabio Efficace, Steven D. Gore, Tae Kon Kim, Naval Daver, Guillermo Garcia-Manero, María Rozman, Alberto Orfao, Sa A. Wang, M. Kathy Foucar, Ulrich Germing, Torsten Haferlach, Phillip Scheinberg, Yasushi Miyazaki, Marcelo Iastrebner, Austin Kulasekararaj, Thomas Cluzeau, Shahram Kordasti, Arjan A. van de Loosdrecht, Lionel Ades, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 998.

https://doi.org/10.1182/blood-2023-186580

Published: 2023

Journal Articles

The Dual Inflammasome/Myddosome Inhibitor HT-6184 Restores Erythropoiesis in MDS/AML

Blood (2023) 142 (Supplement 1): 1417.

https://doi.org/10.1182/blood-2023-182289

Published: 2023

Journal Articles

TLR9-Selective Therapeutic Targeting of MDS Clones with a CpG Payload-Delivery Strategy

Grace A Ward, Sean Christiansen, Gabriela Wright, Sheng Wei, Alan F. List, Kenneth Wright, Erika A Eksioglu

Blood (2022) 140 (Supplement 1): 12306–12307.

https://doi.org/10.1182/blood-2022-170340

Published: 2022

Journal Articles

Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 4588–4589.

https://doi.org/10.1182/blood-2022-165311

Published: 2022

Journal Articles

A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for testing interventions

Blood (2022) 140 (16): 1774–1789.

https://doi.org/10.1182/blood.2021014875

Published: 2022

Includes: Supplemental data

Journal Articles

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Blood (2021) 138 (Supplement 1): 246.

https://doi.org/10.1182/blood-2021-153286

Published: 2021

Journal Articles

Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies

Bijal D. Shah, Caron Jacobson, Scott R. Solomon, Nitin Jain, Mark C. Johnson, Monika Vainorius, Lou Yu, Christopher R. Heery, Alan F. List, Fiona He, Ran Reshef, Luke P. Akard, Craig S. Sauter, Adam J. Olszewski, Abhinav Deol, Koen van Besien

Blood (2021) 138 (Supplement 1): 302.

https://doi.org/10.1182/blood-2021-150609

Published: 2021

Journal Articles

Evidence of NF-ΚB Pathway Activation in Patients with Advanced, High Molecular Risk Myelofibrosis

Jennifer O'Sullivan, Aaron T. Gerds, Claire N. Harrison, Stephen T. Oh, Angela Hamblin, Sarah A Buckley, Alan F. List, Adam J. Mead

Blood (2021) 138 (Supplement 1): 3584.

https://doi.org/10.1182/blood-2021-149666

Published: 2021

Journal Articles

Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL

Nitin Jain, Hagop Kantarjian, Scott R. Solomon, Fiona He, Craig S. Sauter, Christopher R. Heery, Alan F. List, Mark C. Johnson, Yu Lou, Monika Vainorius, Koen van Besien, Adam J. Olszewski, Anthony S. Stein, Bijal D. Shah

Blood (2021) 138 (Supplement 1): 650.

https://doi.org/10.1182/blood-2021-153166

Published: 2021

Journal Articles

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Blood (2020) 136 (24): 2812–2823.

https://doi.org/10.1182/blood.2020006158

Published: 2020

Includes: Supplemental data

Journal Articles

Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia

Blood (2020) 136 (7): 909–913.

https://doi.org/10.1182/blood.2019004352

Published: 2020

Includes: Supplemental data

Journal Articles

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Dasom Lee, MD, Hannah H Asghari, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Rami S. Komrokji, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3894.

https://doi.org/10.1182/blood-2019-127701

Published: 2019

Journal Articles

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Hannah Asghari, MD, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Constance Terrell, PharmD, BCOP, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3895.

https://doi.org/10.1182/blood-2019-130379

Published: 2019

Journal Articles

Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts

David M Swoboda, MD, Jung-Hoon Lee, MD, Onyee Chan, MD, Rami S. Komrokji, MD, Najla Al Ali, M.Sc, Eric Padron, MD, Alan F. List, MD, Mohammad O Hussaini, MD, Jinming Song, MD PhD, David A Sallman, MD

Blood (2019) 134 (Supplement_1): 4244.

https://doi.org/10.1182/blood-2019-124772

Published: 2019

Journal Articles

Dysregulation of Splicing Patterns in MDS Induced By the S100A9/Fto Axis

Erika Adriana Eksioglu, MS PhD, Ling Cen, PhD, Xianghong Chen, PhD, Pingyan Cheng, MD, Kenneth Wright, PhD, Thu Le Trinh, PhD, Danielle Gilvary, BS, Wendy Kandell, BS, Jinhong Liu, MD, Yin-Kai Chen, MD, Amy F McLemore, M.S., Alexandra Calescibetta, John Cleveland, PhD, Alan F. List, MD, Sheng Wei, MD

Blood (2019) 134 (Supplement_1): 4215.

https://doi.org/10.1182/blood-2019-128434

Published: 2019

Journal Articles

A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti-Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML)

Mrinal M Patnaik, MDMBBS, David A Sallman, MD, Abhishek A Mangaonkar, MBBS, Rachel Heuer, Jeffery Hirvela, Darci Zblewski, APRN, C-NP, Aref Al-Kali, MD, Deanna Kanne, Rahil Ismail, Rami S. Komrokji, MD, Adrian Lo, Maria E Balasis, Cameron Durrant, Dale Chappell, Omar Ahmed, Alan F. List, MD, Eric Padron, MD

Blood (2019) 134 (Supplement_1): 4234.

https://doi.org/10.1182/blood-2019-131181

Published: 2019

Journal Articles

Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a

Blood (2019) 134 (Supplement_1): 4220.

https://doi.org/10.1182/blood-2019-128165

Published: 2019

Journal Articles

Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes

Andrew T Kuykendall, MD, Chetasi Talati, MD, Kendra L. Sweet, MD, Eric Padron, MD, David A Sallman, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD

Blood (2019) 134 (Supplement_1): 4177.

https://doi.org/10.1182/blood-2019-123536

Published: 2019

Journal Articles

S100A9 Contributes to T Cell Dysfunction through Its Interaction with RAGE in MDS

Wendy Kandell, BS, Thu Le Trinh, PhD, Xianghong Chen, PhD, Pingyan Cheng, MD, Danielle Gilvary, BS, Yin-Kai Chen, MD, Alexandra Calescibetta, Erika Adriana Eksioglu, MS PhD, Alan F. List, MD, Sheng Wei, MD

Blood (2019) 134 (Supplement_1): 4228.

https://doi.org/10.1182/blood-2019-128717

Published: 2019

NARROW

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

The Dual Inflammasome/Myddosome Inhibitor HT-6184 Restores Erythropoiesis in MDS/AML

TLR9-Selective Therapeutic Targeting of MDS Clones with a CpG Payload-Delivery Strategy

Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma

A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for testing interventions

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies

Evidence of NF-ΚB Pathway Activation in Patients with Advanced, High Molecular Risk Myelofibrosis

Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts

Dysregulation of Splicing Patterns in MDS Induced By the S100A9/Fto Axis

A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti-Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML)

Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a

Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes

S100A9 Contributes to T Cell Dysfunction through Its Interaction with RAGE in MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only